Janux Therapeutics Announces 100% Response in Phase 1a Results for JANX007 in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNew combination improves outcomes for small cell bladder and neuroendocrine prostate cancer patients: early stage but clinical study
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxA Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025